COLUMBIA, Md.--(BUSINESS WIRE)--CELSION CORPORATION (AMEX: CLN) today announced that the company’s ThermoDox liver cancer abstract, “Phase I Study of ThermoDox (Thermally Sensitive Liposomes Containing Doxorubicin) Given Prior to Radiofrequency Ablation for Unresectable Liver Cancers” has been selected for oral presentation in the Awards Session at the 8th Annual International Hepato-Pancreato-Bilary Association (IHPBA) Congress in Mumbai, India from February 27th to March 2nd. (http://www.ihpba2008.com/)
